Abstract
Background
Sildenafil was the only phosphodiesterase-5 inhibitor available for the treatment of pulmonary arterial hypertension (PAH) until the approval and availability of once-daily tadalafil. Since no direct comparative study is likely to be performed between these agents, we sought to evaluate the feasibility of transitioning stable PAH patients from sildenafil to tadalafil.
Methods
The primary end point was continuation on tadalafil without clinical deterioration. A functional outcome through an evaluation of serial change in the 6-min walk test distance (6MWD) was also performed.
Results
Thirty-five patients on sildenafil qualified for the analysis, of which 85.7 % (30/35) were successfully transitioned. The remaining 14.3 % (5/30) (failure group) were switched back to sildenafil due to worsening symptoms. The mean pretransition 6MWD was 363 m, with an average change in the success group of +16.4 m (range = −64 to +140 m) compared to –45 m (range = −123 to +32 m) in the failure group at 1–3 months post switch (p = 0.02). All 30 patients in the success group remained on tadalafil, with an average improvement in the 6MWD of +37.04 m (range = −36.5 to +236.5 m) at 12 months post switch. The failure group had a higher daily sildenafil dose (180 vs. 115.5 mg; p = 0.06), with 42.8 % of patients at the highest sildenafil dose failing the transition.
Conclusion
The transition from sildenafil to tadalafil is safe and generally well tolerated. Patients with more severe disease and those on higher doses of sildenafil are more likely to fail the transition and should be monitored closely post switch.
Similar content being viewed by others
Abbreviations
- 6MWD:
-
Six-minute walk test distance
- mPAP:
-
Mean pulmonary artery pressure
- PAH:
-
Pulmonary arterial hypertension
- PH:
-
Pulmonary hypertension
References
McGoon M, Gutterman D, Steen V et al (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):14S–34S
Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6):1917–1928
Barst RJ, Gibbs JS, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(1):S78–S84
Galiè N, Ghofrani HA, Torbicki A et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353(20):2148–2157
Barst RJ, Oudiz RJ, Beardsworth A et al (2011) Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30(6):632–643
Rubin LJ, Badesch DB, Fleming TR et al (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 140(5):1274–1283
Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 32(1):198–209
Francis SH, Sekhar KR, Ke H, Corbin JD (2011) Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. Handb Exp Pharmacol 200:93–133
Castro PF, Greig D, Verdejo HE et al (2011) Intrapulmonary shunting associated with sildenafil treatment in a patient with idiopathic pulmonary arterial hypertension. Thorax 66(12):1097–1098
Ghofrani HA, Voswinckel R, Reichenberger F et al (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44(7):1488–1496
Du Boi RM, Weycker D, Albera C et al (2011) 6-Minute walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183(9):1231–1237
Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ (2008) Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 32:637–643
Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A (2009) A meta-analysis of randomised controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394–403
Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487–492
Conflict of interest
Dr.O. A Shlobin serves on the Speakers’ Bureau for Lung Rx, United Therapeutics, and Actelion. Dr. S. D. Nathan has received research funding from, is on the Speakers’ Bureau for, and has served as a consultant for United Therapeutics and LungRx. He is also on the Speakers’ Bureau for Actelion and Gilead. A. W. Brown, N. Weir, S. Ahmad, and M. Lemma have no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shlobin, O.A., Whitney Brown, A., Weir, N. et al. Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical Considerations. Lung 190, 573–578 (2012). https://doi.org/10.1007/s00408-012-9408-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-012-9408-6